Heart Test Laboratories

HSCS

Börsenwert 14,6 Mio. $

Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) for its MyoVista® wavECGTM device as a 12-lead resting electrocardiograph. The clearance covers the acquisition and interpretation of ECG signals from adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements provided to clinicians on an advisory basis.

FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. (“Fortitude” or the “Company”), a vertically-integrated digital asset mining platform anchored in Zcash, today announced the appointment of Kimberly Pittman as Chief Legal Officer, effective September 28. Pittman joins Fortitude's executive leadership team as the Company prepares for its previously announced proposed business combination with HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”). In her role, Pittman will work along.

Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026

HeartSciences Inc. (HSCS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.58 per share a year ago.

Fortitude purchased approximately $1,000,000 of HeartSciences' shares of common stock at $2.43 per share, a 22% premium to the closing price on the purchase date The exchange ratio under the merger agreement with Fortitude is unchanged, and no additional shares will be issued to holders of Fortitude's equity interests at closing as a result of the investment Following the investment, Fortitude holds approximately 9.4% of HeartSciences' outstanding shares of common stock Southlake, TX, Aug. 19, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that on August 12, 2026 Fortitude Mining Holdings, Inc. (“Fortitude”) purchased 411,522 shares of HeartSciences' common stock for an aggregate purchase price of approximately $1,000,000 in a private placement (the “Investment”). The shares were issued at a negotiated price of $2.43 per share, representing a 22% premium to the closing price of HeartSciences' common stock on the purchase date.

Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch of the MyoVista Insights platform and submission of the MyoVista wavECG device to the FDA for 510(k) clearance

Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow

FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction (the “Proposed Transaction”) which is expected to close in H2 2026. Upon closing, the combined company will operate under the Fortitud.

Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function

Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy